ACM
STRO icon

ADAR1 Capital Management’s Sutro Biopharma STRO Stock Holding History

ADAR1 Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Sell
404,014
-120,427
-23% -$3.75M 0.61% 39
2026
Q1 		$13.1M Buy
524,441
+457,364
+682% +$8.27M 0.77% 31
2025
Q4 		$776K Buy
+67,077
New +$637K 0.06% 155

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

ADAR1 Capital Management's STRO Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Sutro Biopharma (STRO) stake by 23% in Q2 2026, selling an estimated $3.75M and leaving 404,014 shares worth $13.4M. The position accounts for 0.61% of the portfolio, ranked #39.

ADAR1 Capital Management first reported a position in STRO in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • ADAR1 Capital Management held 404,014 shares of Sutro Biopharma worth $13.4M as of Q2 2026.
  • ADAR1 Capital Management sold 120,427 Sutro Biopharma shares in Q2 2026, an estimated $3.75M.
  • Sutro Biopharma made up 0.61% of ADAR1 Capital Management's portfolio in Q2 2026, its #39 holding.
  • ADAR1 Capital Management first reported a position in Sutro Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.